Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Asset Writedowns and Impairment (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with -$54000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 96.26% year-over-year to -$54000.0, compared with a TTM value of $413000.0 through Dec 2025, up 745.31%, and an annual FY2025 reading of $413000.0, up 745.31% over the prior year.
  • Asset Writedowns and Impairment was -$54000.0 for Q4 2025 at Cytek Biosciences, down from $132000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $912000.0 in Q1 2024 and bottomed at -$1.4 million in Q4 2024.
  • Average Asset Writedowns and Impairment over 5 years is $98000.0, with a median of $155000.0 recorded in 2021.
  • The sharpest move saw Asset Writedowns and Impairment skyrocketed 467.24% in 2022, then crashed 279.93% in 2023.
  • Year by year, Asset Writedowns and Impairment stood at $155000.0 in 2021, then soared by 89.68% to $294000.0 in 2022, then plummeted by 279.93% to -$529000.0 in 2023, then plummeted by 172.59% to -$1.4 million in 2024, then soared by 96.26% to -$54000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for CTKB at -$54000.0 in Q4 2025, $132000.0 in Q3 2025, and $21000.0 in Q2 2025.